Dr Reddy’s CEO for branded markets (India and emerging markets), MV Ramana said: “India is among the top five countries in the world in terms of disease burden of NPC, which is a rare form of ...

In 2023, Dr. Reddy ... with disease progression on or after platinum-containing chemotherapy. M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy ...

and India is among the top five countries in the world in terms of disease burden,’‘ M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s said in a ...

Dr. Reddy’s Laboratories RDY is a major player ... agreements with Sanofi for vaccine distribution and Bayer for heart failure drug vericiguat, in India. RDY partnered with Alvotech for the ...

BMJ study As pollution levels rise across the country and the burden of heart disease, especially among the young grows in India – we speak to Dr K. Srinath Reddy, cardiologist and distinguished ...

Dr. Reddy’s Laboratories Ltd. on Thursday announced ... of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Dr. Reddy’s Laboratories has recently become ... is a groundbreaking advancement in NPC treatment. With a growing disease burden in India, this therapy provides much-needed hope to patients ...